Clinical Trial Concierge Web Page Launch
The NMD4C are excited to announce that the new clinical trial (CT) Concierge web page is now live!
The role of the CT Concierge is to act as an information broker for clinical trials for all Canadian clinical care sites and to support the NMD4C community with consistent knowledge, awareness, and access to information across sites.
This position is independently objective and designed to serve as an impartial resource, not funded by industry and is for all NM stakeholders.
The Concierge role was created to strengthen the clinical trial landscape and be a resource to all key stakeholders. A key priority of the concierge will be to work with Investigators to develop solutions to barriers associated with bringing neuromuscular clinical trials to Canada.
Visit the Concierge web page here, and discover the benefits of working with the Concierge for investigators, patients and families, industry, and other stakeholders.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.